findmyKOL

Emil Tanghetti, MD

Enriched profile

Board-certified dermatologist; Director, Center for Dermatology and Laser Surgery · Center for Dermatology and Laser Surgery

ORCIDNPI
Region🇺🇸 Sacramento, CA · West · United StatesSpecialtyDermatologyFocusAcne and Rosacea Treatments and Effects+4
Active KOLfindmyKOL typefindmyKOL type: our influence ranking, shown when you reveal the full profileLatest publication2025Online presenceverified 2026Payments2021–2025NIH fundingNone on fileWhy? →

Emil Tanghetti is Board-certified dermatologist; Director, Center for Dermatology and Laser Surgery at Center for Dermatology and Laser Surgery. OpenAlex indexes 196 publications with 3,221 citations (h-index 33); ClinicalTrials.gov lists 2 registered studies with this person as an investigator.

Data verified 14 Aug 2026

Overview

Updated 27 Aug 2026

Emil Tanghetti, MD, is Board-certified dermatologist at Center for Dermatology and Laser Surgery, Sacramento, CA. The public record shows 196 publications with 3,221 citations (h-index 33), centered on Acne and Rosacea Treatments and Effects, Dermatologic Treatments and Research, Skin Protection and Aging. It also documents an investigator role on 2 registered clinical trials, industry payments reported by 37 companies.

  • Most recent indexed publication: 2025 · Lasers in surgery and medicine
  • Top research focus: Acne and Rosacea Treatments and Effects
  • 2 registered trials on ClinicalTrials.gov
  • Open Payments reporting from 37 companies

Generated from the cited public record · current as of 27 Aug 2026. Every fact links its source below.

Indications focus

from trials led + research topics
Acne / Hidradenitis2 trialsAcne Vulgaris2 trialsCicatrix2 trialsStriae Distensae1 trialAtopic Dermatitis / Eczema

Research focus

OpenAlex concept fingerprint
Acne and Rosacea Treatments and EffectsDermatologic Treatments and ResearchSkin Protection and AgingDermatology and Skin Diseasesmelanin and skin pigmentation

Drugs & molecules

across trials, industry payments and publications
Arazlogeneric · TazaroteneClinical trialsIndustry payments24Publications3Akliefgeneric · TrifaroteneClinical trialsIndustry payments10Publications1Altrenogeneric · TretinoinClinical trialsIndustry payments6Publications1

Works with

trial sponsors and companies reporting payments
Abbvie Inc.Clinical trialsIndustry payments249Incyte CorporationClinical trialsIndustry payments128Janssen Biotech, Inc.Clinical trialsIndustry payments96

Scholarship

indexed output and impact (OpenAlex)
View publications ↓
196publications

Distinct works indexed by OpenAlex, matched via ORCID; 2 in PubMed.

3,221citations

Total citations across indexed works.

33h-index

Hirsch index (OpenAlex). i10-index 70.

Clinical & industry

trials, payments and federal funding
2clinical trials

Investigator role on registered studies.

View trials
37companies · 2021–2025

Companies reporting payments to CMS. Facts, not judgments.

View payments
0NIH grants

Federally funded research awards.

Contact

The practice address and phone this provider lists in the federal NPPES (CMS) registry.

Practice address

Telephone

Practice address and telephone from the federal NPPES registry.

Sign in to view contact details →

Clinical trials

Updated 27 Aug 2026

Listed as an investigator on 2 registered studies on ClinicalTrials.gov. The most recent:

Industry payments

Updated 27 Aug 2026

37 companies reported payments to CMS in program years 2021–2025. These are public disclosures, not judgments. The latest:

Medicare prescribing footprint (2024)

The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.

  • Anti-infectives

    38.5%
    Tetracycline-class Drug16.6%
    Doxycycline Monohydrate77%Doxycycline Hyclate19%Doxycycline Ir-Dr4%
    Part D<11 patients
    Azole Antifungal10.2%
    Ketoconazole100%
    Part D117 patients
  • Cancer & immunology

    19.6%
    Nucleoside Metabolic Inhibitor8.7%
    Fluorouracil100%
    Part D140 patients
    Porphyrin Precursor3.8%
    Aminolevulinic acid hcl100%
    Part B, office-administered52 patients
  • Sensory organs

    17.7%
    Corticosteroid17.7%
    Clobetasol Propionate46%Hydrocortisone43%Betamethasone Diprop Augmented7%Clobetasol Emollient4%
    Part D<11 patients
4 more therapeutic areas behind the reveal.Reveal →
Where care is delivered (Part B)0% facility · 100% office

Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.

NIH funding

We didn't find any NIH-funded research awards for this person in NIH RePORTER. Why? →

Publications

Updated 27 Aug 2026

Their five most recent publications, matched to their ORCID record and linked to PubMed.

Network

Updated 27 Aug 2026

The people this person publishes with most, by number of co-authored papers. Names link to their own profile when we have one.

Online presence

Updated 27 Aug 2026

This person's own public accounts first, then places where others mention them. Two different things, listed separately.

Owned accounts

public accounts run by this person
  • LinkedIn

    linkedin.com/in/emiltanghetti

    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →linkedin.com
  • Doximity

    doximity.com/pub/emil-tanghetti-md

    provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →doximity.com
  • ResearchGate

    researchgate.net/profile/Emil-Tanghetti

    provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →researchgate.net

Mentions by others

where others cite or feature them
  • Instagram

    instagram.com/centerfordermandlasersurgery

    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →instagram.com

We list an account only when the public record ties it to this person. verified means we've confirmed the match in more than one place; provisional means it looks right but we're still confirming.

Background & recognition

Updated 27 Aug 2026

Credentials, appointments and honors, newest first, each linked to the public source it came from.

Education

degrees and training on record

Editorial & leadership roles

journal and society appointments
  • Fellow

    American Academy of Dermatology

    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →dermatologyandlasersurgery.com
  • Fellow

    American Society for Laser Medicine and Surgery

    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →dermatologyandlasersurgery.com
  • Member

    California Medical Association

    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →dermatologyandlasersurgery.com
2 more roles behind the reveal.Reveal →

Awards & honors

honors on the public record
1 more award behind the reveal.Reveal →

Secondary affiliations

appointments beyond the home institution
1 more affiliation behind the reveal.Reveal →

Media & interviews

press, podcasts and appearances
1 more media item behind the reveal.Reveal →

Every item links to where we found it. verified means we've confirmed it in more than one place; provisional means we found it and are still confirming.

Similar KOLs

Other experts from the same institution or the same specialty.